business / news / / The Manila Times
Phase 3 trials for chronic weight management planned for initiation in the second half of 2026.
Petrelintide will enter Phase 3 trials for chronic weight management in the second half of 2026.
KEY POINTS
- The ZUPREME-1 Phase 2 trial showed petrelintide achieved double-digit weight loss with placebo-like tolerability.
- A Phase 2 trial of petrelintide combined with enicepatide is planned for the second quarter of 2026.
- Petrelintide is formulated for once-weekly dosing with stability that allows co-formulation with other peptides.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →